Li J, Le AK, Chaung KT, et al. - In this retrospective study, researchers examined the impact of nonalcoholic fatty liver disease (NAFLD) on complete viral suppression [(CVS), HBV DNA < 20-100 IU/mL] and/or biochemical response [(BR), ALT of ≤ 25 U/L for females; 35 U/L for males] in chronic hepatitis B (CHB) individuals who received oral antiviral therapy. The sample consisted of 555 treated CHB patients (187 NAFLD; 368 non-NAFLD) from 2000 to 2016 at a USA medical center. NAFLD patients vs non-NAFLD were more likely HBeAg negative, hypertensive, male with a higher mean BMI. Concomitant NAFLD had no effect on CVS and/or BR long-term rates in treated CHB patients. Receipt of entecavir or tenofovir (vs older therapies) and lower baseline HBV DNA or higher ALT were positively linked to achieving CVS or BR.